Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.30 |
| ▸ | DRD3 | P35462 | 3/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD5 | P21918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440740 | 0.86 | PNMT (0.39) | PNMTALDH1A1MAPT | |
| SCHEMBL1011335 | 0.70 | ALDH1A1 (0.52) | PNMTALDH1A1MAPT | |
| SCHEMBL19534811 | 0.67 | CES1 (0.37) | PNMTDRD2DRD3TAAR1DRD1 | |
| Hydrochloric Acid SCHEMBL31564468 | 0.64 | TAAR1 (0.35) | PNMTTAAR1 | |
| SCHEMBL18300330 | 0.64 | TAAR1 (0.35) | PNMTALDH1A1TAAR1 | |
| SCHEMBL2259507 | 0.64 | PNMT (0.42) | PNMTTAAR1 | |
| SCHEMBL8023204 | 0.64 | DRD2 (0.35) | PNMTALDH1A1MAPTDRD2DRD3 | |
| SCHEMBL6434186 | 0.63 | HTT (0.46) | ALDH1A1 | |
| SCHEMBL20558326 | 0.63 | MAPT (0.37) | ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL31564071 | 0.63 | DRD2 (0.34) | PNMTDRD2DRD3TAAR1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947689-B2 | Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-05-24 | — | — | US | disclosed |
| EP-2054421-B1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2054421-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015270-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| EP-1288203-B1 | Cyclic nitrones and pharmaceutical compositions containing them | AVENTIS PHARMA INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1288203-A1 | Cyclic nitrones and pharmaceutical compositions containing them | Aventis Pharmaceuticals Inc. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-5962469-A | PREVENTION OF OXIDATION TISSUE DAMAGE BY FREE RADICALS | HOECHST MARION ROUSSEL INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0863878-A1 | CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST MARION ROUSSEL, INC. (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997010218-A1 | CYCLIC NITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST MARION ROUSSEL, INC. (US) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039476-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM3, GRM1 | PNMT 1648/4885ALDH1A1 4053/4885MAPT 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.